CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
Panobinostat +1 moredrug
Likely dose
Panobinostat 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02032810
NCT02032810Phase 1Completed
CompareCT.gov

A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Jan 10, 2014·Updated Jan 20, 2023

In Brief

A Phase 1 clinical trial evaluating Panobinostat and Ipilimumab for Melanoma and Skin Cancer. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if an investigational drug called panobinostat can be given safely with another drug called ipilimumab. Investigators want to learn more about the side effects of this combination of drugs using different doses of panobinostat and the same dose of ipilimumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma, Skin Cancer
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 10, 2014
Enrollment StartJan 7, 2014
Primary CompletionSep 6, 2017
Study CompletionSep 25, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 12.5 years ago

Interventions

Panobinostatdrug

Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.

Ipilimumabdrug

Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.